These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8413595)

  • 1. Rhône-Poulenc lifts Institut Mérieux stake.
    Ward M
    Nature; 1993 Oct; 365(6446):478. PubMed ID: 8413595
    [No Abstract]   [Full Text] [Related]  

  • 2. Rhône-Poulenc to focus biotech work on gene therapy.
    Butler D
    Nature; 1994 May; 369(6476):92. PubMed ID: 8177328
    [No Abstract]   [Full Text] [Related]  

  • 3. Industrial R&D paradigm shift to vaccines.
    Maggon K
    Biotechnol J; 2009 Apr; 4(4):458-61. PubMed ID: 19370719
    [No Abstract]   [Full Text] [Related]  

  • 4. Current situation and use of autogenous vaccines in France: the views of the manufacturer and the user.
    Thibault E
    Dev Biol (Basel); 2004; 117():73-81. PubMed ID: 15597620
    [No Abstract]   [Full Text] [Related]  

  • 5. Indian-born weapons for infectious diseases.
    Padmanaban G
    Nat Med; 2003 Jul; 9(7):813. PubMed ID: 12835687
    [No Abstract]   [Full Text] [Related]  

  • 6. Report predicts burgeoning vaccine markets.
    Dove A
    Nat Med; 2001 Aug; 7(8):877. PubMed ID: 11479604
    [No Abstract]   [Full Text] [Related]  

  • 7. The costs and economics of modern vaccine development.
    Batson A
    Dev Biol (Basel); 2002; 110():15-24. PubMed ID: 12477302
    [No Abstract]   [Full Text] [Related]  

  • 8. Merck opts for shake-up to clear drug pipeline.
    Nature; 2005 Dec; 438(7071):1076-7. PubMed ID: 16371975
    [No Abstract]   [Full Text] [Related]  

  • 9. An audience with... Rino Rappuoli.
    Rappuoli R
    Nat Rev Drug Discov; 2007 Sep; 6(9):694. PubMed ID: 17907342
    [No Abstract]   [Full Text] [Related]  

  • 10. Life Sciences Alliance World 2007--a Terrapinn conference.
    Searle B; Shumoogam J
    IDrugs; 2007 Jun; 10(6):370-2. PubMed ID: 17641997
    [No Abstract]   [Full Text] [Related]  

  • 11. Aligning pharmaceutical innovation with medical need.
    Nathan C
    Nat Med; 2007 Mar; 13(3):304-8. PubMed ID: 17342145
    [No Abstract]   [Full Text] [Related]  

  • 12. Vaccine venture boosts health hopes.
    Butler D
    Nature; 2009 Sep; 461(7262):323. PubMed ID: 19759588
    [No Abstract]   [Full Text] [Related]  

  • 13. The future of best investing in vaccines: the Health Technology Assessment approach.
    La Torre G; de Waure C; Chiaradia G; Mannocci A; Specchia ML; Nicolotti N; Ricciardi W
    Vaccine; 2008 Mar; 26(13):1609-10. PubMed ID: 18289744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moncef Slaoui.
    Slaoui M; Mullard A
    Nat Rev Drug Discov; 2015 Jul; 14(7):452-3. PubMed ID: 26129795
    [No Abstract]   [Full Text] [Related]  

  • 15. The U.S. vaccine supply.
    Schwartz HK
    N Engl J Med; 2005 Mar; 352(10):1046-7; author reply 1046-7. PubMed ID: 15762001
    [No Abstract]   [Full Text] [Related]  

  • 16. Wyeth Pharmaceutical's perspective on vaccine production.
    Stiles GL
    Md Med; 2005; 6(1):22-3. PubMed ID: 15869103
    [No Abstract]   [Full Text] [Related]  

  • 17. A view from industry.
    Chapek ML
    Dev Biol (Basel); 2002; 111():189-93. PubMed ID: 12678240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The winning shot. New vaccine technologies to offer pinpoint attacks on a variety of potentially deadly diseases.
    Kirchheimer B
    Mod Healthc; 2005 Nov; 35(46):52-4. PubMed ID: 16334833
    [No Abstract]   [Full Text] [Related]  

  • 19. A place in the sun.
    Abbott A
    Nature; 2007 Mar; 446(7132):124-5. PubMed ID: 17344823
    [No Abstract]   [Full Text] [Related]  

  • 20. Long wait almost over. Project Bioshield measure nears final approval.
    Fong T
    Mod Healthc; 2004 Jul; 34(29):18-9. PubMed ID: 15301143
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.